Clinical Trial Update: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

View source ↗

Summary

Open-label expanded access treatment with pegunigalsidase alfa for Fabry disease is described, providing therapy to patients outside of a traditional randomized…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Pegunigalsidase alfa (pegunigalsidase alfa)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Fabry Disease | Status: APPROVED_FOR_MARKETING